How to Choose the Right Preclinical CRO (5 Considerations!)
/The Preclinical Contract Research Organization (CRO) market is growing and expected to eclipse USD 11.3 billion by 2033, according to Research and Markets in Yahoo! Finance. With thousands of preclinical CROs in the US alone, selecting the right preclinical CRO becomes one of your most important decisions. This is especially true when the future of a new therapy depends on the quality and reliability of preclinical development.
Having been involved in this space for more than 40 years, it is easy to see how the right preclinical CRO partner helps biotech, pharma, universities, and research groups move forward with confidence. Making the wrong choice here has the potential to slow progress, drain capital, and effectively create uncertainty at some of the most critical moments.
To help inform this process, the team at TSRL put together five (5) considerations that truly matter when evaluating a preclinical CRO for early-stage innovation.
Consideration 1: They Should Show Real Scientific Depth
Capabilities listed on a website are one thing, but showing true scientific depth needs to start with a conversation. If your program hinges on exposure, metabolism, or delivery challenges, your CRO should demonstrate and be able to speak to hands-on expertise in those specific areas. In the initial conversation, consider the following:
Bioanalysis: Ask how methods are developed. Are assays tailored to your compound’s properties? Can the team build sensitive, reproducible methods that support low concentration detection?
Formulation Development: Solubility and stability issues appear early in many programs. A strong preclinical CRO will evaluate formulation options that improve exposure and enable meaningful in vivo studies. Thoughtful solubility screening and prototype development can prevent months of frustration later.
PK ADME and Toxicology: PK data should guide strategy. A preclinical CRO partner should connect in vitro findings to in vivo outcomes and help interpret what the data means for dose selection and next steps. Ask detailed questions on their approach.
Consideration 2: Look for Integration Across Disciplines
Fragmentation creates delays. When one vendor runs formulation and another runs bioanalysis, important insights can get lost.
An integrated preclinical CRO aligns formulation, PK, and bioanalysis under one coordinated plan. If a metabolite profile raises questions, the team can adjust formulation or study design quickly. That responsiveness protects timelines and budgets.
Integrated thinking reduces friction and keeps programs moving.
Consideration 3: Flexible Study Design Helps Early On
Early-stage development rarely follows a straight line. Funding cycles can shift, hypotheses can evolve, and new data will ultimately reshape the direction of it all.
Any preclinical CRO should design fit for purpose studies that match the specific stage of drug development. For instance, exploratory toxicology may make sense before committing to larger programs, and elements like tiered validation approaches can conserve capital expenditures.
Teams that understand grant funded research through the National Institutes of Health (NIH), for instance, also recognize milestone driven budgets and structured reporting requirements. That experience matters when working with specific governmental programs.
Consideration 4: Understand Why Preclinical Studies Fail
It can be hard to imagine, but 90 percent of preclinical candidates fail to reach approval, largely due to a combination of scientific and translational challenges. Many compounds demonstrate promising activity in early laboratory models but fail to replicate that effect in humans because animal models do not always predict clinical outcomes. Safety liabilities often emerge as development progresses, including off target toxicity or unfavorable pharmacokinetics that were not fully understood at the outset. In other cases, poor bioavailability, formulation limitations, or inadequate target validation undermine efficacy.
The fact is, preclinical studies shape the foundation for IND submissions, and clinical study design should reflect future regulatory expectations. When looking for a new preclinical CRO partner, ask the following:
How is documentation prepared?
How are data packages structured?
How does regulatory guidance inform study planning?
Teams that think ahead often are able to reduce rework and position programs for smoother transitions later on. The goal is to have regulatory awareness embedded in the process.
Consideration 5: Pay Attention to How They Communicate
A strong preclinical CRO helps you decide what to move forward and what to pause. That often starts with clear data interpretation. It includes early identification of risk, and it also requires honest conversations about feasibility and next steps.
Sponsors benefit from partners who understand portfolio management and capital discipline. The right preclinical CRO connects today’s data to future milestones so decisions support the desired long-term value.
In our experience, long-term partnerships grow through consistency in timelines, transparent budgeting, high quality data, and regular updates. For instance, having honest, direct conversations when results surprise everyone strengthens that confidence even further.
Choosing the right preclinical CRO can shape the trajectory of your entire program. Early decisions carry long term consequences, so the partner you select should bring clarity, accountability, and forward thinking at every step. When your CRO aligns with your goals and treats your innovation with care, you create the conditions for smarter development and stronger outcomes.
For questions regarding this article or to speak to a preclinical CRO expert, message us here.
